Compare Charles River Laboratories Intl. Inc (CRL) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Nu Holdings Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Nu Holdings Ltd trades at $15.5 (market cap $74.30B). The key difference: Nu Holdings Ltd is far larger — about 5.2× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Nu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Nu Holdings Ltd for 53 Days on average.
| CRL | NU | |
|---|---|---|
Market Cap | $14.23B | $74.30B |
Volume | 1,176,885 | 80,294,805 |
Sector | Health | Financials |
52-Week High | $310.77 | $18.76 |
52-Week Low | $149.93 | $11.60 |
Typical Hold Time | 33 Days | 53 Days |
Enterprise Value | $17.06B | $96.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
NU Holdings (NU) trades at $15.58, down 0.51% on the day, as the Brazilian digital bank navigates market volatility. The stock shows strong fundamental momentum with revenue growing from $3.0B in 2022 to $10.6B in 2025 and net income turning positive to $2.9B. Technical indicators are mixed with a bullish moving average signal but overbought RSI conditions. Recent news highlights acquisition speculation and Goldman Sachs' bullish $19 price target.
NU presents a compelling growth story with expanding profitability and analyst support, though risks include credit concentration and acquisition uncertainty. The stock trades near consensus targets with 57% buy ratings, suggesting moderate upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
